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Abstract
Introduction: Studies on the association of a polymorphism in codon 72 of the p53 tumour suppressor gene (rs1042522)
with cervical neoplasia have inconsistent results. While several methods for genotyping p53 exist, they vary in accuracy and
are often discrepant.
Methods: We used latent class models (LCM) to examine the accuracy of six methods for p53 determination, all conducted
by the same laboratory. We also examined the association of p53 with cytological cervical abnormalities, recognising
potential test inaccuracy.
Results: Pairwise disagreement between laboratory methods occurred approximately 10% of the time. Given the estimated
true p53 status of each woman, we found that each laboratory method is most likely to classify a woman to her correct
status. Arg/Arg women had the highest risk of squamous intraepithelial lesions (SIL). Test accuracy was independent of
cytology. There was no strong evidence for correlations of test errors.
Discussion: Empirical analyses ignore possible laboratory errors, and so are inherently biased, but test accuracy estimated
by the LCM approach is unbiased when model assumptions are met. LCM analysis avoids ambiguities arising from empirical
test discrepancies, obviating the need to regard any of the methods as a ‘‘gold’’ standard measurement. The methods we
presented here to analyse the p53 data can be applied in many other situations where multiple tests exist, but where none
of them is a gold standard.
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Introduction
A polymorphism (rs1042522) in codon 72 of the p53 tumour
suppressor gene (Arg72Pro) has been extensively studied as a risk
factor for cervical cancer and its precancerous lesions, but the
results have been largely inconsistent [1,2]. Although a variety of
laboratory methods for establishing p53 status exist, they vary with
respect to their reliability, in terms of inherent accuracy and under
different assay and specimen conditions. Using more than one
method can lead to discrepancies in the estimate of a subject’s p53
codon 72 genotype, which leads to irresolvable ambiguities about
how one should best estimate the association between this genetic
marker and cervical neoplasia. A recent editorial [3] has suggested
that problems of this type are widespread in genetic testing. In the
face of these ambiguities, it is not clear which method (if any)
might be preferred to assess this association, or which might
provide the best estimate of the disease odds ratio (OR).
Furthermore, because empirical estimates of the association ignore
the possibility of test errors, they are inevitably subject to bias. By
using a latent class model (LCM) that incorporates information
from multiple imperfect tests, we can evaluate the accuracy of
alternative test methods, and improve the assessment of the
association of the genetic marker with disease. In this paper, we
develop a LCM approach to this type of data, and illustrate the
results from a study of the relation between p53 polymorphism and
disease.
We previously investigated the variation between laboratories in
determining p53 genotype from split samples originating from the
same sample of women enrolled in a case-control study [4]. In that
work, three international laboratories used the same, standardised
laboratory procedure to ascertain the genotype. Discrepancies
between laboratory results for the same woman were not
infrequent, leading to uncertainty about how to best represent
the association of p53 with cervical cancer. Our analytical
approach was to use a LCM [5–11], which avoids the need to
regard any of the laboratories as a gold standard or in any way
superior to the others, but instead takes the inaccuracies of each
laboratory into account. The sensitivity and specificity of each
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laboratory’s data were estimated by the LCM, and the model also
adjusted the disease OR for the laboratory measurement errors.
LCMs have been widely used in many areas of medical research
for situations in which a gold standard diagnosis of disease cannot
be achieved, or where there are problems involved in measuring
risk factors. The statistical estimation of the LCM model
parameters is based on maximum likelihood, which implies some
optimality in the results. Specifically, under a correctly specified
model, maximum likelihood estimates are asymptotically unbiased
and have maximum precision. The LCM also avoids the
ambiguities caused by discrepancies in results that occur when
multiple tests are used.
In this paper, we describe several LCMs used to examine the
discrepancies between six competing laboratory methods for p53
determination, all conducted blindly by the same laboratory. The
model strategy provides estimates of accuracy for each alternative
test method, even though all of them are potentially subject to
error. The strength of the method is that, in doing so, we are not
required to incorrectly assume that any of the methods represents
a preferred or ‘gold’ standard measurement.
As a secondary objective we examine the association of p53 with
cervical abnormalities found on cytology, again taking inaccuracy
of the data into account. Finally, we compare the results yielded by
the latent class models with the empirical associations. The latter
ignore the possibility of laboratory errors; again, this is obviously
problematic, because the existence of discrepancies in test results
for the same woman indicates that errors do in fact occur, and
which therefore bias the empirical OR estimates.
The methods we propose are generalizable to other situations
where multiple, imperfect tests exist and when it is unreasonable to
assume a gold standard measure.
Materials and Methods
Ethics Statement
We used a subset of data from the Ludwig-McGill cohort study
of human papillomavirus (HPV) infection and cervical intrae-
pithelial neoplasia [12,13]. Subjects entered the study only after
giving signed informed consent. All of the study procedures and
the informed consent were approved by the institutional review
boards and ethical committees of the participating institutions:
McGill University, Montreal, Quebec, Canada; the University of
Toronto, Toronto, Ontario, Canada; and the Ludwig Institute for
Cancer Research and the MEVNC clinic, both in Sa˜o Paulo,
Brazil.
Epidemiological Study
The original study cohort consists of 2528 women aged 18–60
years (median = 33 years) from a maternal and child health
program for low income families in Sao Paulo, Brazil. The racial
composition of the study was comparable to that in the source
population. Most women were of white (European), black, and
mixed (mulata) ancestry, with less than 2% being of other
ancestries. Cervical and blood samples were obtained, together
with questionnaires, at the initial enrolment into the study, at
follow-up visits every four months during the first year, and then
twice yearly thereafter for at least eight years (with questionnaires
at annual follow-up returns). This sampling was done on an
unselected basis from the population of screened women, and
hence is free from genetic selection bias. At the time the specimens
were tested for this report there had been 24,545 visits from 2462
women, with a mean of ten visits per subject and 149,184 women
months of follow-up (mean= 61 months, median = 76 months).
We limited the dataset to women who had at least four out of six
possible visits in the first two years of follow-up. More information
on the study design and methods for the original study can be
found elsewhere [12].
The outcome of interest in the Ludwig McGill study was two-
year cumulative risk of squamous intraepithelial lesions (SIL).We
chose to exclude women whose worst cytology outcomes were
Atypical Squamous Cells of Undetermined Significance (ASCUS)
or Atypical Glandular Cells of Undetermined Significance
(AGUS), because their results lie somewhere between the case
and non-case outcomes used in our analysis. We felt that there
would not be a benefit to including ASCUS and AGUS because
these are ambiguous cases in which cytology was equivocal. We
believe that the best comparison to examine effects of the
polymorphism is by contrasting the non-equivocal categories of
lesion outcome. The polymorphism in question is not a marker of
disease but potentially of susceptibility to HPV and in consequence
to disease.
p53 Codon 72 Genotyping
We assayed DNA samples from 963 women, comprising those
with long term follow-up and complete cytological and HPV DNA
testing results at the end of 2002, after the exclusions described
above. Details of the genotyping methods are described elsewhere
[14]. In brief, we amplified a 279 base-pair fragment of exon 4 of
p53 by a polymerase chain reaction protocol (PCR). P53 codon 72
genotyping of the amplified products was done in all samples by
four methods: (i) denaturing high-performance liquid chromatog-
raphy (DHPLC), (ii) dot blot hybridization (DBH) with sequence-
specific oligonucleotide probes for p53Arg and p53Pro, (iii)
restriction fragment length polymorphism (RFLP) analysis after
cleavage of the PCR products with the BsaJI endonuclease (RFLP-
1) and (iv) with the BstUI endonuclease (RFLP-2). Two additional
genotyping assays were also conducted in a subset of 144 women
for whom sufficient DNA was available for extended testing. These
include direct sequencing (DS) of the exon 4 amplified product
and allele-specific PCR (AS-PCR).
Our analysis focused on the first four laboratory methods
(DHPLC, DBH, RFLP-1, and RFLP-2). However, other analyses
were carried out incorporating the additional data for the subset of
women in which the DS and AS-PCR methods were also
performed.
No research has been done on the determinants of error for
these methods, however a separate paper by our laboratory
colleagues describes the relative value of these methods from an
assay performance perspective [14]. They each represent a balance
between simplicity of the assay versus biological accuracy (i.e.,
sensitivity and specificity for the nucleotide sequences that identify
the genotypes). Other than the usual work done to establish each
technique in the laboratory to make sure that they work suitably
based on performance standards and appropriate controls, there
has been no systematic work on the repeatability of the assays in
our lab or, to our knowledge, in other labs. That being said, these
techniques represent legitimate alternative ways of analyzing p53
codon 72 polymorphism (rs1042522).
Statistical Analysis
We first examined the pattern of disagreements between the
results of the alternative test methods. Crude and chance-corrected
levels of agreement were calculated using weighted kappa statistics
using Cicchetti and Allison weights [15,16]. In our primary
analyses, we considered the genotype results as a variable with 3
levels (Arg/Arg, Arg/Pro, and Pro/Pro). The Arg/Arg genotype has
been associated with increased risk of cervical neoplasia in many
previous studies [1,2].
Latent Class Modelling of p53 Data
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In our latent class models, a woman’s true p53 status is the latent
(unobserved) variable, and the probability of being classified into
the three possible levels of the p53 status by each method is
estimated for each woman, conditional on her true status. These
probabilities are then combined over the various possible levels of
the actual status, according to the model specifications; this
combination forms the contribution to the overall likelihood of the
data from a particular woman. For instance, if the tests are
assumed to be independent, the likelihood contribution is made up
of a set of products of probabilities of the individual test results,
with each set corresponding to the actual p53 status of a given
woman; the sets are summed across levels of actual p53 status,
using weights that correspond to the prevalences of the various p53
genotypes.
Finally, following standard maximum likelihood methods, the
logarithms of the likelihood contributions are summed over study
participants, and this sum is maximised numerically to obtain
estimates of the model parameters. The model parameters include
the probabilities of particular test results for a woman with given
p53 status, and the prevalence of the various p53 genotypes in the
sample. Optionally, correlations between the test errors for
different methods can also be incorporated. Further technical
details of the latent class model approach are given elsewhere
[6,11].
Our Model 1 uses the results from the four main laboratory
methods used in the study (DHPLC, DBH, RFLP-1, RFLP-2)
without assuming any of them to be more or less accurate than the
others. The sensitivity and specificity of each test is estimated,
relative to the true p53 status. Model 2 augments the data used in
Model 1 by additionally incorporating the cytology results. It
examines the relationship between the true p53 status (which is
again the latent variable) and cytology. The effect of the true p53
status is evaluated through the two-year cumulative risk of SIL for
each p53 value, and by the odds ratios of SIL between pairs of p53
values. Both Models 1 and 2 assume that the accuracy of the
testing methods is independent of a woman’s cytology results. This
assumption is later relaxed in a further analysis, as described below
in the section, ‘‘Analyses of robustness’’.
For comparison with the LCM findings, we consider the
empirical data, but without invoking a latent variable. For each
method, the empirical approach examines the observed p53 status
and its association with the cytology outcome, ignoring the
possibility of errors in the laboratory results. The association with
cytology is assessed for each test method separately, using the
empirical OR between the apparent genotype and cytology.
Finally, we executed a similar series of models to examine test
accuracy using the subset of women for whom two additional test
results (using the AS-PCR and DS methods) were available.
Analyses of Robustness
To check the robustness of our model results and examine
model assumptions, several secondary analyses were carried out.
First, Model 1 was repeated after excluding cases of SIL from the
dataset, and changes in the model estimates were noted. Second,
Model 1 was repeated using all women in the study, so that they
were not excluded based on their cytology status or number of
visits.
Third, Models 1 and 2 were repeated to allow test accuracy to
vary by cytology status, with likelihood ratio tests being used to
assess the statistical significance of this variation. For completeness,
we also fitted Models 1 and 2 with test accuracy constrained to be
constant across tests; likelihood ratio tests were again used to test
the hypothesis of constant accuracy.
Fourth, Models 1 and 2 assume that the tests are conditionally
independent, given the true p53 status of an individual. To test this
assumption, we fit extended LCMs that added correlation terms to
represent the conditional associations of pairs of test results for
women in each of the p53 groups. Likelihood ratio tests were used
to evaluate if the model fit was significantly improved by the
inclusion of these correlations.
Finally, two further sets of analyses were carried out with the
p53 polymorphism being re-grouped into only two categories (first,
into Arg/Arg vs. others, and second, into Pro/Pro vs. others, these
being consistent with the expectation of risk associations as
reported in the literature [2]). This was done because although the
total sample size in this study was substantial, when polymorphism
status was analysed at three levels for each test, some cross-
classified cell frequencies were nevertheless small (particularly
when the cytology result was included in the model), leading to
some model instability and convergence problems. Aggregation of
the data into fewer test levels alleviated many of these difficulties,
while still providing useful results.
Results
Our analyses were conducted with the R statistical package [17]
and the software program LEM [18]. R was used to examine test
agreement while LEM was used to run all of the models, including
both the LCMs and the empirical models that do not allow for test
inaccuracy.
Agreement of Test Results
Table 1 shows cross-tabulations of the p53 results from each pair
of the 4 main laboratory tests, subdivided by cytology status, and
with p53 taken as a variable with 3 levels for the test result.
Although the majority of these pairwise test results are concordant,
discrepancies were not uncommon.
Table 2 summarises the pairwise test data in terms of crude and
chance corrected agreement levels. The crude agreement was 90%
or better in all cases, while the weighted kappa statistics ranged
between 0.84 and 0.92. While this pattern is encouraging overall,
the disagreements between pairs of tests that occurs for
approximately 10% of women is clearly problematic. Further-
more, when more than two tests are done, the chance of
disagreement between any two tests increases substantially.
Accuracy of Laboratory Test Methods
Table 3 shows the results of the latent Model 1 fitted to the
available data from four main tests (DHPLC, DBH, RFLP-1, and
RFLP-2). Each cell in the table shows the estimated classification
probability for each of the three possible genotype test results (i.e.,
Arg/Arg, Arg/Pro, Pro/Pro), for each laboratory test and for each of
the three possible genotype status levels. For instance, women who
are truly Arg/Arg are estimated to have a 96.4% chance of being
classified as Arg/Arg by the DHPLC method, a 2.8% chance of
being classified as Arg/Pro, and a 0.8% chance of being classified as
Pro/Pro.
For each of the tests, the model suggests that the most likely
classification of any given woman is to her correct p53 status. To
clarify, the LCM estimates the probability that a woman’s true
status is each of: Arg/Arg, Arg/Pro and Pro/Pro. The estimate with
the highest probability, conditional on her true status, is the most
likely test classification for a woman with that true status. We
found that across the entire sample, the estimated true status is
equal to the most likely test classification. Furthermore, the overall
accuracy is reasonably high. The accuracy is high for all three p53
genotypes for tests DHPLC and DBH. For test RFLP-1,
Latent Class Modelling of p53 Data
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performance is slightly inferior to the other tests for women who
are truly Pro/Pro; they have approximately a 10% chance of being
incorrectly classified as Arg/Pro, and an accuracy of only 89% with
this method. For test RFLP-2, the classifications are less accurate
for Arg/Arg women, for whom there is an accuracy of only 84%;
women in this group may be classified as Arg/Pro with probability
approximately 14%. Note that all of the standard errors for these
estimated probabilities are small, mostly in the range of 1–2%.
However, some caution should be exercised in interpreting these
results, because a few model parameters were on a boundary, with
an associated zero probability of misclassification for certain data
combinations (e.g. the incorrect classification of Arg/Pro women
into the Pro/Pro category by test DHPLC).
It is reassuring that the most likely classification of a given
woman by a laboratory test is to her true p53 genotype status.
Moreover, it is interesting to note that the least likely classification
for homozygous Arg/Arg women is to its most dissimilar result (Pro/
Pro), and vice versa, with intermediate probabilities for the
heterogeneous Arg/Pro group.
Genotype – Cytology Relationship
Table 4 shows estimates of the cumulative two-year risk of SIL
for each level of p53, based on Model 2. Also shown are the
associated ORs and standard errors from this LCM, for the Arg/
Arg and Arg/Pro groups against the Pro/Pro reference category. The
results indicate that the homozygous Arg/Arg women have the
highest risk, with an OR of 1.89, while women in the heterozygous
Table 1. Cross tabulation of genotyping test results across four laboratory methods and by cytology status.
Cytology Status
Negative Cytology (SIL =1) Any Grade SIL (SIL =2)
Second Test Rating Second Test Rating
First Test Rating Arg/Arg Pro/Arg Pro/Pro Missing Arg/Arg Pro/Arg Pro/Pro Missing
First test: DHPLC Arg/Arg 308 5 8 0 31 0 1 0
Second test: DBH Pro/Arg 9 365 9 0 1 21 1 0
Pro/Pro 3 4 139 0 0 0 6 0
First test: DHPLC Arg/Arg 299 15 7 0 30 1 1 0
Second test: RFLP-1 Pro/Arg 18 360 5 0 1 21 1 0
Pro/Pro 5 15 126 0 0 1 5 0
First test: DHPLC Arg/Arg 258 49 13 1 29 1 2 0
Second test: RELP-2 Pro/Arg 9 361 13 0 0 22 1 0
Pro/Pro 4 2 140 0 0 0 6 0
First test: DBH Arg/Arg 302 16 2 0 31 1 0 0
Second test: RFLP-1 Pro/Arg 16 355 3 0 0 21 0 0
Pro/Pro 4 19 133 0 0 1 7 0
First test: DBH Arg/Arg 262 50 7 1 29 2 1 0
Second test: RFLP-2 Pro/Arg 7 354 13 0 0 21 0 0
Pro/Pro 2 8 146 0 0 0 8 0
First test: RFLP-1 Arg/Arg 266 46 9 1 28 2 1 0
Second test: RFLP-2 Pro/Arg 3 365 22 0 1 21 1 0
Pro/Pro 2 1 135 0 0 0 7 0
doi:10.1371/journal.pone.0056430.t001
Table 2. Pairwise comparison of agreement among laboratory methods using crude agreement percentages and kappa
coefficients.
Kappa Coefficient (ASE)
Laboratory methods compared Crude Agreement (%) Unweighted Weighted
DHPLC and DBH 0.95 0.93 (0.01) 0.92 (0.04)
DHPLC and RFLP-1 0.92 0.88 (0.01) 0.88 (0.04)
DHPLC and RFLP-2 0.90 0.84 (0.02) 0.84 (0.04)
DBH and RFLP-1 0.93 0.89 (0.01) 0.9 (0.04)
DBH and RFLP-2 0.90 0.84 (0.02) 0.86 (0.04)
RFLP-1 and RFLP-2 0.90 0.85 (0.02) 0.85 (0.04)
doi:10.1371/journal.pone.0056430.t002
Latent Class Modelling of p53 Data
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Arg/Pro group have an OR that is elevated only slightly above 1. It
is important to note again that these parameters are maximum
likelihood estimates, and take the possibility of laboratory errors
into account. These ORs avoid the ambiguity associated with
different empirical OR values from different methods, as discussed
below. In addition to the parameters shown in Table 4, this model
also gave estimates of test accuracy. Those results were very similar
to those from Model 1, so details are not shown here.
Table 5 shows the empirical prevalences of each level of p53 in
the case and non-case groups of the study across the four
laboratory tests. Also shown are the empirical ORs for each test,
for Arg/Arg and Arg/Pro against the referent Pro/Pro group. The
results are quite consistent with those of the LCM (see Table 4),
but there is some variation among tests in their estimated
prevalences and OR values which would lead to ambiguity if
only the empirical results were calculated. For example, the Arg/
Arg genotype was associated with ORs around 2 for each test,
except for DHPLC which had a somewhat higher value (OR of
2.43). The ORs for the Arg/Pro group were lower; the DHPLC,
RFLP-1 and RFLP-2 methods had values close to 1, but the
DHPLC method showed an approximately 50% increase in SIL
risk (OR of 1.46) associated with the Arg/Pro genotype. When
compared with the LCM based estimate from Table 4 (OR of
1.09) one might suspect that the DHPLC method is least accurate
and presents the most biased results when considered in isolation.
Extension to 6 Test Methods
Table 6 shows the Model 1 results for the two additional
laboratory tests (AS-PCR and DS) that were used less frequently in
this study (only for the subset of cases with sufficient DNA material
for expanded genotyping assays). The data for the four earlier tests
were also included in this analysis, giving a total of six possible tests
for a given woman. The accuracy estimates for the four earlier
tests were very similar to those shown already, so these numerical
details are omitted from Table 6.
The results of Table 6 show that, like the previous four tests, AS-
PCR and DS have their highest classification probabilities
associated with the actual p53 value for a given woman, but their
accuracy appears to be somewhat lower than for the other four
tests. For example, a woman who is Arg/Arg has a 92% probability
of correct classification by the AS-PCR test, and a 90% probability
with the DS test, compared to 96%, 97%, and 96% associated
with DHPLC, DBH and RFLP-1 respectively. Similarly, the
correctness rates for Pro/Pro women (79% for AS-PCR and 90%
for DS) are inferior to the earlier tests. As seen with the other tests,
Table 3. Classification probabilities (standard errors) for p53
genotype by four laboratory tests, according to true p53
status: results from Model 1.
True p53 status (X)
Test Probability Arg/Arg Arg/Pro Pro/Pro
P(Arg/Arg|X) 0.964(0.010) 0.006(0.005) 0.040(0.016)
DHPLC P(Arg/Pro|X) 0.028(0.009) 0.994(0.005) 0.037(0.015)
P(Pro/Pro|X) 0.008(0.005) 0.000* 0.923(0.021)
P(Arg/Arg|X) 0.997(0.009) 0.011(0.005) 0.000(0.000)
DBH P(Arg/Pro|X) 0.020(0.006) 0.978(0.008) 0.026(0.013)
P(Pro/Pro|X) 0.006(0.004) 0.012(0.006) 0.974(0.013)
P(Arg/Arg|X) 0.957(0.011) 0.023(0.008) 0.013(0.009)
RFLP-1 P(Arg/Pro|X) 0.037(0.010) 0.977(0.008) 0.102(0.024)
P(Pro/Pro|X) 0.006(0.004) 0.000* 0.886(0.025)
P(Arg/Arg|X) 0.839(0.020) 0.000* 0.006(0.006)
RFLP-2 P(Arg/Pro|X) 0.138(0.018) 0.978(0.008) 0.014(0.010)
P(Pro/Pro|X) 0.023(0.008) 0.022(0.008) 0.980(0.011)
*Boundary solution: estimated values of zero for probability and its standard
error.
doi:10.1371/journal.pone.0056430.t003
Table 4. Cumulative 2-year risk (standard errors) of SIL by p53
genotype: results from Model 2.
p53 genotype SIL risk (SE) OR (CI*)
Arg/Arg 0.090(0.015) 1.89(0.38, 3.40)
Arg/Pro 0.054(0.011) 1.09(0.19, 1.99)
Pro/Pro 0.050(0.017) reference
*95% confidence interval.
doi:10.1371/journal.pone.0056430.t004
Table 5. Prevalence (standard error) of p53 genotypes in case
and non-case groups, and empirical ORs, for four laboratory
tests.
Prevalence (SE)
p53 genotype Test Cases Non-cases OR (CI)
Arg/Arg DHPLC 0.525(0.064) 0.378(0.017) 2.43(0.25–4.61)
DBH 0.525(0.064) 0.377(0.017) 1.95(0.40–3.50)
RFLP-1 0.509(0.064) 0.379(0.017) 1.90(0.29–3.51)
RFLP-2 0.475(0.064) 0.319(0.016) 1.97(0.44, 3.50)
Arg/Pro DHPLC 0.377(0.062) 0.451(0.017) 1.46(0.13, 2.79)
DBH 0.344(0.061) 0.440(0.017) 1.10(0.18, 2.02)
RFLP-1 0.377(0.062) 0.459(0.017) 1.16(0.16, 2.16)
RFLP-2 0.377(0.062) 0.485(0.017) 1.03(0.21, 1.85)
Pro/Pro DHPLC 0.098(0.038) 0.172(0.013) reference
DBH 0.131(0.043) 0.184(0.013) reference
RFLP-1 0.115(0.041) 0.162(0.013) reference
RFLP-2 0.148(0.045) 0.196(0.014) reference
doi:10.1371/journal.pone.0056430.t005
Table 6. Classification probabilities (standard errors) for p53
genotype by two additional laboratory tests, according to
true p53 status: results from Model 1 with extended dataset.
True p53 status: X (SE)
Test Arg/Arg Arg/Pro Pro/Pro
AS-PCR P(Arg/Arg|X) 0.915(0.037) 0.044(0.030) 0.071(0.048)
P(Arg/Pro|X) 0.052(0.029) 0.852(0.052) 0.138(0.064)
P(Pro/Pro|X) 0.033(0.023) 0.104(0.044) 0.791(0.076)
DS P(Arg/Arg|X) 0.895(0.041) 0.054(0.030) 0.000*
P(Arg/Pro|X) 0.105(0.041) 0.946(0.030) 0.101(0.055)
P(Pro/Pro|X) 0.000* 0.000* 0.899(0.055)
*Boundary solution: estimated values of zero for probability and its standard
error.
doi:10.1371/journal.pone.0056430.t006
Latent Class Modelling of p53 Data
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AS-PCR and DS also have intermediate misclassification proba-
bilities associated with the heterogeneous group, and the smallest
misclassification probabilities for Arg/Arg women being classified
into Pro/Pro and vice versa. Overall, the results suggest that AS-PCR
and DS are somewhat less accurate than any of the four previous
methods, but in light of the restricted dataset in which these
comparisons were made it would not be prudent to make
generalizations concerning assay accuracy. Note that some of
the estimated probabilities in Table 6 are zero, indicating that
further boundaries have been encountered. This may imply that
the model parameters and their standard errors may be somewhat
inaccurate, especially considering the smaller number of women
with six test results available, and the correspondingly larger
number of parameters required by this extended model.
Robustness of Results
Given the difficulty of obtaining reliable estimates of accuracy
specific to the SIL cases, we ran additional models after excluding
them, to assess the robustness of the main results. These additional
models yielded test accuracy values that were very similar to those
when the SIL cases were included, such as in Table 1, and we
therefore conclude that the inclusion of the SIL cases made no
material difference to the results. Similarly, when all women were
included, regardless of cytology status or number of visits, the
results were again very similar, indicating no important impact of
these exclusion criteria.
When Model 1 was extended by additionally allowing the test
accuracy parameters to depend on cytology status, it failed to
converge with the available data, and thus it did not provide
estimates for the accuracy parameters. However, we do not expect
genotype test accuracy to depend on cytology, especially when
considering that one’s genotype may have been measured before
abnormal cytology results were documented during follow-up.
When Models 1 and 2 were constrained to have constant accuracy
parameters across test methods, there was a significant de-
terioration in the fit to the data (relative to the corresponding
unconstrained model), indicating that an assumption of equal test
accuracy was untenable.
The extended models that allowed for possible correlations
between test errors typically showed no significant improvement in
the model fit. The one exception was the suggestion of an
interaction between the DHPLC and DBH methods. However, we
had no a priori reason to expect a correlation between this
particular pair of tests. Bearing in mind that there are 6 pairwise
correlations between the 4 tests, a multiple comparisons adjust-
ment to the p-value of the DHPLC-DBH association renders it
non-significant. Overall we conclude that there is no strong
evidence for correlated test errors, and that the results from models
assuming conditional independence are valid.
When the analyses were repeated using the p53 latent variable
at only 2 levels (Arg/Arg vs. Arg/Pro and Pro/Pro combined, or Pro/
Pro vs. Arg/Arg and Arg/Pro combined) the corresponding estimates
of classification probabilities were very similar to those shown in
Table 3, but with the advantage that no parameters hit their
boundaries of an estimated zero probability. This suggests that
although several of the parameters fall on the boundary in the
Model 1 results with three levels for p53, the other estimates are
trustworthy, despite the greater demands on the data by a model
with three levels for p53 as opposed to only two.
Discussion
Since 1998 [19], there have been numerous studies examining
the association between p53 codon 72 genotype (rs1042522) and
risk of cervical cancer or precancer. Although the association is
biologically plausible because of the different binding affinities to
the E6 gene of HPV by the resulting Arg and Pro products, there
has been considerable heterogeneity in risk estimates across studies
[1,2]. At least some of the heterogeneity may have been due to
variations in accuracy and reproducibility of the different assays
available to genotype this polymorphism, which prompted us to
examine the issue using a data modelling approach in a study in
which multiple assays were used to genotype p53. Our work in
examining the variability in genotyping methods was prompted by
the state of uncertainty in the literature at the time. More recent
work indicated that although plausible the association may not be
real or may be too small to be of clinical relevance [2].
Furthermore, the issue of population stratification, in which race
confounds the relationship between p53 status and the outcome,
could bias our effect estimates. As previous studies have found that
allele frequencies vary across ethnic groups and that the risk of
cervical cancer varies by ethnicity it could be the case that
population stratification may have biased the effect estimate.
Among the three primary racial groups, we found very little
difference in the risk of the outcome (risk varied between 8 and
10%) and preliminary analyses of the same data showed that race
and age-adjusted effect estimated did not vary importantly from
crude estimates (data not shown). However, irrespective of the true
nature of the relation between p53 codon 72 polymorphism and
cervical neoplasia, we believe that the LCM methodology reported
here is a useful tool to examine the relation between disease and
a biomarker that is measured with error.
The main advantage of applying the LCM approach to this
dataset is that it provides detailed estimates of the accuracy of each
laboratory method. In particular, the models yield estimates of the
probability of correct or incorrect classification of the p53
genotype, from each level of the actual genotype variable to each
possible observed value, for each test. We are therefore able to
assess and compare the performance of each method, but without
incorrectly assuming any one of the tests to be a reference or gold
standard.
In this study we found that each method had the highest
probability of classifying a given woman into her actual p53
category; the least likely misclassifications were from actual Arg/Arg
into apparent Pro/Pro, and vice versa. However, the tests did vary
significantly in their accuracy. In our analysis, the DHPLC and
DBH laboratory methods were very accurate across levels of p53
status, while the RFLP-1 and RFLP-2 methods were slightly
inferior as they misclassified women of a particular p53 status
more than 10% of the time.
We also tried to investigate if test accuracy depended on
whether a woman had abnormal cytology or not. The number of
SIL cases was relatively small, which limited our capability to
demonstrate such an effect, if it exists; however, it is reasonable to
assume that test accuracy does not depend on cytology, especially
considering that abnormalities may not have been present when
the genotype was measured.
The LCM analyses also provide estimates of the OR between
the p53 genotype and cervical abnormalities, taking possibility of
genotype measurement errors into account. These ORs are based
on the ensemble of available test information for each woman,
and, being based on maximum likelihood principles, enjoy
asymptotic unbiasedness and optimally maximal precision for
a correctly specified model. In contrast, the empirical estimates of
the OR are based on the subset of data from each method in turn.
The empirical test-specific estimates inevitably vary (e.g. the
DHPLC test shows substantially higher ORs than the other
frequently used tests), and so it is not immediately obvious which
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test would be preferred in order to convey the risk associated with
the p53 genotypes. The empirical OR estimates were slightly less
precise than the corresponding LCM values, because the former
are based on a more limited portion of the data than the LCM,
which exploits the information from all available tests simulta-
neously.
Failure of the model to converge when test accuracy was
allowed to depend on the cytology result probably reflects the very
limited number of SIL cases, because a much larger number of
parameters is then required in the extended model. While we are
unable to say unequivocally if test accuracy depends on cytology,
given the type of specimens used in this study (DNA extracted
from exfoliated cervical cells of asymptomatic women with at most
low volume lesions) and its cohort design (lesions detected mostly
at time points that were different than when the genotyping
specimen was obtained), we believe it is reasonable to assume that
test accuracy is actually independent of cytology.
The methods we have employed on the Ludwig-McGill study
data are quite general, and could be applied in other situations
where a gold standard measurement of a risk marker (genetic or
otherwise) is not possible. Application of the basic LCM requires
that three or more independent tests be available for each subject
[6,20]; in this study we had at least four tests per woman.
The basic model assumes that the test errors are conditionally
independent, given the true (but unobserved) status of an
individual, which is a plausible expectation. If more than three
tests are available, the assumption can be tested by additionally
including correlation terms in the LCM, and then assessing the
improvement in fit through a likelihood ratio test. Although the
assumption of conditionally independent errors has been raised as
a concern in the application of the LCM method, a number of
investigations [21–23] have shown that the assumption may
sometimes actually be a reasonable one, or that the model is robust
to misspecification in this regard. In the hypothetical situation of
a general pattern of positive correlation among tests, the analysis
would overestimate test accuracy both in terms of sensitivity and
specificity. However, in our earlier work on p53 [4] we found no
evidence of such correlations between the test results for the same
woman, using the same method in different laboratories. The
likelihood of such correlations between different laboratory
methods is presumably smaller, and indeed the analysis in this
paper revealed no convincing evidence of correlated errors.
Overall, latent class models are useful for assessing the accuracy
of various test procedures without assuming a gold standard. In
addition, these methods can provide an adjusted, unbiased
estimate of the odds ratio. While each test on its own is imperfect,
the adjusted OR estimated by the LCM accounts for this test
inaccuracy by taking advantage of the information presented by
having an ensemble of testing methods upon which to base its
result.
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